Acura Pharmaceuticals, Inc.
Acura Pharmaceuticals, Inc. ACUR Peers
See (ACUR) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ACUR | $0.02 | N/A | 1.3M | -1.00 | -$0.02 | N/A |
| MKGAF | $131.45 | +0.73% | 57.2B | 17.91 | $7.34 | +1.64% |
| MKKGY | $26.13 | -1.40% | 56.4B | 17.78 | $1.47 | +2.14% |
| HLNCF | $5.62 | +1.08% | 50.7B | 26.76 | $0.21 | +1.96% |
| TKPHF | $26.30 | -18.15% | 41.4B | 55.96 | $0.47 | +5.06% |
| IPSEY | $29.30 | N/A | 38.8B | 24.21 | $1.21 | +1.04% |
| SDZNY | $48.89 | -0.66% | 21.1B | -2444.50 | -$0.02 | +1.37% |
| TEVJF | $17.80 | -7.82% | 20.4B | -15.48 | -$1.15 | N/A |
| ESALY | $61.51 | -2.11% | 17.6B | 20.54 | $3.00 | N/A |
| SGIOY | $8.19 | -1.33% | 13.9B | 11.70 | $0.70 | +0.85% |
Stock Comparison
ACUR vs MKGAF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, MKGAF has a market cap of 57.2B. Regarding current trading prices, ACUR is priced at $0.02, while MKGAF trades at $131.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas MKGAF's P/E ratio is 17.91. In terms of profitability, ACUR's ROE is +0.00%, compared to MKGAF's ROE of +0.10%. Regarding short-term risk, ACUR is more volatile compared to MKGAF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs MKKGY Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, MKKGY has a market cap of 56.4B. Regarding current trading prices, ACUR is priced at $0.02, while MKKGY trades at $26.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas MKKGY's P/E ratio is 17.78. In terms of profitability, ACUR's ROE is +0.00%, compared to MKKGY's ROE of +0.10%. Regarding short-term risk, ACUR is more volatile compared to MKKGY. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs HLNCF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, HLNCF has a market cap of 50.7B. Regarding current trading prices, ACUR is priced at $0.02, while HLNCF trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas HLNCF's P/E ratio is 26.76. In terms of profitability, ACUR's ROE is +0.00%, compared to HLNCF's ROE of +0.09%. Regarding short-term risk, ACUR is more volatile compared to HLNCF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs TKPHF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, TKPHF has a market cap of 41.4B. Regarding current trading prices, ACUR is priced at $0.02, while TKPHF trades at $26.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas TKPHF's P/E ratio is 55.96. In terms of profitability, ACUR's ROE is +0.00%, compared to TKPHF's ROE of +0.03%. Regarding short-term risk, ACUR is more volatile compared to TKPHF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs IPSEY Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, IPSEY has a market cap of 38.8B. Regarding current trading prices, ACUR is priced at $0.02, while IPSEY trades at $29.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas IPSEY's P/E ratio is 24.21. In terms of profitability, ACUR's ROE is +0.00%, compared to IPSEY's ROE of +0.17%. Regarding short-term risk, ACUR is more volatile compared to IPSEY. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs SDZNY Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, SDZNY has a market cap of 21.1B. Regarding current trading prices, ACUR is priced at $0.02, while SDZNY trades at $48.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas SDZNY's P/E ratio is -2444.50. In terms of profitability, ACUR's ROE is +0.00%, compared to SDZNY's ROE of +0.00%. Regarding short-term risk, ACUR is more volatile compared to SDZNY. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs TEVJF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, TEVJF has a market cap of 20.4B. Regarding current trading prices, ACUR is priced at $0.02, while TEVJF trades at $17.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas TEVJF's P/E ratio is -15.48. In terms of profitability, ACUR's ROE is +0.00%, compared to TEVJF's ROE of -0.21%. Regarding short-term risk, ACUR is more volatile compared to TEVJF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs ESALY Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, ESALY has a market cap of 17.6B. Regarding current trading prices, ACUR is priced at $0.02, while ESALY trades at $61.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas ESALY's P/E ratio is 20.54. In terms of profitability, ACUR's ROE is +0.00%, compared to ESALY's ROE of +0.06%. Regarding short-term risk, ACUR is more volatile compared to ESALY. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs SGIOY Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, SGIOY has a market cap of 13.9B. Regarding current trading prices, ACUR is priced at $0.02, while SGIOY trades at $8.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas SGIOY's P/E ratio is 11.70. In terms of profitability, ACUR's ROE is +0.00%, compared to SGIOY's ROE of +0.08%. Regarding short-term risk, ACUR is more volatile compared to SGIOY. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs SGIOF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, SGIOF has a market cap of 12.9B. Regarding current trading prices, ACUR is priced at $0.02, while SGIOF trades at $15.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas SGIOF's P/E ratio is 10.94. In terms of profitability, ACUR's ROE is +0.00%, compared to SGIOF's ROE of +0.08%. Regarding short-term risk, ACUR is more volatile compared to SGIOF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs BIOVF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, BIOVF has a market cap of 10.4B. Regarding current trading prices, ACUR is priced at $0.02, while BIOVF trades at $30.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas BIOVF's P/E ratio is 25.45. In terms of profitability, ACUR's ROE is +0.00%, compared to BIOVF's ROE of +0.10%. Regarding short-term risk, ACUR is more volatile compared to BIOVF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs IPSEF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, IPSEF has a market cap of 10.4B. Regarding current trading prices, ACUR is priced at $0.02, while IPSEF trades at $125.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas IPSEF's P/E ratio is 26.23. In terms of profitability, ACUR's ROE is +0.00%, compared to IPSEF's ROE of +0.14%. Regarding short-term risk, ACUR is more volatile compared to IPSEF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs SFOSF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, SFOSF has a market cap of 8.5B. Regarding current trading prices, ACUR is priced at $0.02, while SFOSF trades at $1.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas SFOSF's P/E ratio is 13.13. In terms of profitability, ACUR's ROE is +0.00%, compared to SFOSF's ROE of +0.06%. Regarding short-term risk, ACUR is more volatile compared to SFOSF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs ESALF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, ESALF has a market cap of 7.8B. Regarding current trading prices, ACUR is priced at $0.02, while ESALF trades at $27.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas ESALF's P/E ratio is 24.12. In terms of profitability, ACUR's ROE is +0.00%, compared to ESALF's ROE of +0.03%. Regarding short-term risk, ACUR is more volatile compared to ESALF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs ESAIY Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, ESAIY has a market cap of 7.7B. Regarding current trading prices, ACUR is priced at $0.02, while ESAIY trades at $6.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas ESAIY's P/E ratio is 24.00. In terms of profitability, ACUR's ROE is +0.00%, compared to ESAIY's ROE of +0.03%. Regarding short-term risk, ACUR is more volatile compared to ESAIY. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs HKMPY Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, HKMPY has a market cap of 6.5B. Regarding current trading prices, ACUR is priced at $0.02, while HKMPY trades at $58.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas HKMPY's P/E ratio is 18.23. In terms of profitability, ACUR's ROE is +0.00%, compared to HKMPY's ROE of +0.16%. Regarding short-term risk, ACUR is more volatile compared to HKMPY. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs HKMPF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, HKMPF has a market cap of 6.1B. Regarding current trading prices, ACUR is priced at $0.02, while HKMPF trades at $27.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas HKMPF's P/E ratio is 17.22. In terms of profitability, ACUR's ROE is +0.00%, compared to HKMPF's ROE of +0.16%. Regarding short-term risk, ACUR is more volatile compared to HKMPF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs GZPHF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, GZPHF has a market cap of 5.7B. Regarding current trading prices, ACUR is priced at $0.02, while GZPHF trades at $2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas GZPHF's P/E ratio is 9.57. In terms of profitability, ACUR's ROE is +0.00%, compared to GZPHF's ROE of +0.07%. Regarding short-term risk, ACUR is more volatile compared to GZPHF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs APNHF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, APNHF has a market cap of 5.4B. Regarding current trading prices, ACUR is priced at $0.02, while APNHF trades at $12.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas APNHF's P/E ratio is 20.07. In terms of profitability, ACUR's ROE is +0.00%, compared to APNHF's ROE of +0.04%. Regarding short-term risk, ACUR is more volatile compared to APNHF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs WIBFF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, WIBFF has a market cap of 5B. Regarding current trading prices, ACUR is priced at $0.02, while WIBFF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas WIBFF's P/E ratio is -0.01. In terms of profitability, ACUR's ROE is +0.00%, compared to WIBFF's ROE of +0.00%. Regarding short-term risk, ACUR is less volatile compared to WIBFF. This indicates potentially lower risk in terms of short-term price fluctuations for ACUR.
ACUR vs HLBBF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, HLBBF has a market cap of 4.5B. Regarding current trading prices, ACUR is priced at $0.02, while HLBBF trades at $5.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas HLBBF's P/E ratio is 11.96. In terms of profitability, ACUR's ROE is +0.00%, compared to HLBBF's ROE of +0.13%. Regarding short-term risk, ACUR is more volatile compared to HLBBF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs LVZPF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, LVZPF has a market cap of 4B. Regarding current trading prices, ACUR is priced at $0.02, while LVZPF trades at $3.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas LVZPF's P/E ratio is 11.43. In terms of profitability, ACUR's ROE is +0.00%, compared to LVZPF's ROE of +0.15%. Regarding short-term risk, ACUR is more volatile compared to LVZPF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs HLUBF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, HLUBF has a market cap of 3.5B. Regarding current trading prices, ACUR is priced at $0.02, while HLUBF trades at $3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas HLUBF's P/E ratio is 7.71. In terms of profitability, ACUR's ROE is +0.00%, compared to HLUBF's ROE of +0.13%. Regarding short-term risk, ACUR is more volatile compared to HLUBF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs INVVY Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, INVVY has a market cap of 3B. Regarding current trading prices, ACUR is priced at $0.02, while INVVY trades at $21.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas INVVY's P/E ratio is -62.42. In terms of profitability, ACUR's ROE is +0.00%, compared to INVVY's ROE of -0.01%. Regarding short-term risk, ACUR is more volatile compared to INVVY. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs APNHY Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, APNHY has a market cap of 2.9B. Regarding current trading prices, ACUR is priced at $0.02, while APNHY trades at $6.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas APNHY's P/E ratio is 11.80. In terms of profitability, ACUR's ROE is +0.00%, compared to APNHY's ROE of +0.05%. Regarding short-term risk, ACUR is more volatile compared to APNHY. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs IZQVF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, IZQVF has a market cap of 2.9B. Regarding current trading prices, ACUR is priced at $0.02, while IZQVF trades at $20.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas IZQVF's P/E ratio is -56.68. In terms of profitability, ACUR's ROE is +0.00%, compared to IZQVF's ROE of -0.01%. Regarding short-term risk, ACUR is more volatile compared to IZQVF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs HMDCF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, HMDCF has a market cap of 2.8B. Regarding current trading prices, ACUR is priced at $0.02, while HMDCF trades at $3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas HMDCF's P/E ratio is -64.10. In terms of profitability, ACUR's ROE is +0.00%, compared to HMDCF's ROE of -0.01%. Regarding short-term risk, ACUR is more volatile compared to HMDCF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs HYPMY Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, HYPMY has a market cap of 2.7B. Regarding current trading prices, ACUR is priced at $0.02, while HYPMY trades at $4.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas HYPMY's P/E ratio is 19.14. In terms of profitability, ACUR's ROE is +0.00%, compared to HYPMY's ROE of +0.07%. Regarding short-term risk, ACUR is more volatile compared to HYPMY. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs DNPUF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, DNPUF has a market cap of 2.6B. Regarding current trading prices, ACUR is priced at $0.02, while DNPUF trades at $6.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas DNPUF's P/E ratio is 15.55. In terms of profitability, ACUR's ROE is +0.00%, compared to DNPUF's ROE of -1.05%. Regarding short-term risk, ACUR is more volatile compared to DNPUF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs ULIHF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, ULIHF has a market cap of 2.5B. Regarding current trading prices, ACUR is priced at $0.02, while ULIHF trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas ULIHF's P/E ratio is 7.00. In terms of profitability, ACUR's ROE is +0.00%, compared to ULIHF's ROE of +0.21%. Regarding short-term risk, ACUR is more volatile compared to ULIHF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs THCBF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, THCBF has a market cap of 2.4B. Regarding current trading prices, ACUR is priced at $0.02, while THCBF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas THCBF's P/E ratio is -0.10. In terms of profitability, ACUR's ROE is +0.00%, compared to THCBF's ROE of +0.00%. Regarding short-term risk, ACUR is less volatile compared to THCBF. This indicates potentially lower risk in terms of short-term price fluctuations for ACUR.
ACUR vs HTSUF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, HTSUF has a market cap of 2.4B. Regarding current trading prices, ACUR is priced at $0.02, while HTSUF trades at $32.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas HTSUF's P/E ratio is 15.60. In terms of profitability, ACUR's ROE is +0.00%, compared to HTSUF's ROE of +0.05%. Regarding short-term risk, ACUR is more volatile compared to HTSUF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs CHSYF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, CHSYF has a market cap of 2.2B. Regarding current trading prices, ACUR is priced at $0.02, while CHSYF trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas CHSYF's P/E ratio is 6.65. In terms of profitability, ACUR's ROE is +0.00%, compared to CHSYF's ROE of +0.09%. Regarding short-term risk, ACUR is more volatile compared to CHSYF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs TSMRF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, TSMRF has a market cap of 2.1B. Regarding current trading prices, ACUR is priced at $0.02, while TSMRF trades at $28.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas TSMRF's P/E ratio is 13.03. In terms of profitability, ACUR's ROE is +0.00%, compared to TSMRF's ROE of +0.07%. Regarding short-term risk, ACUR is more volatile compared to TSMRF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs DMPHF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, DMPHF has a market cap of 2.1B. Regarding current trading prices, ACUR is priced at $0.02, while DMPHF trades at $39.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas DMPHF's P/E ratio is 18.15. In terms of profitability, ACUR's ROE is +0.00%, compared to DMPHF's ROE of +0.20%. Regarding short-term risk, ACUR is more volatile compared to DMPHF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs LJUIF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, LJUIF has a market cap of 2.1B. Regarding current trading prices, ACUR is priced at $0.02, while LJUIF trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas LJUIF's P/E ratio is 13.97. In terms of profitability, ACUR's ROE is +0.00%, compared to LJUIF's ROE of +0.19%. Regarding short-term risk, ACUR is more volatile compared to LJUIF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs LBTSF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, LBTSF has a market cap of 1.9B. Regarding current trading prices, ACUR is priced at $0.02, while LBTSF trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas LBTSF's P/E ratio is 150.17. In terms of profitability, ACUR's ROE is +0.00%, compared to LBTSF's ROE of +0.01%. Regarding short-term risk, ACUR is more volatile compared to LBTSF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs SHEZF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, SHEZF has a market cap of 1.7B. Regarding current trading prices, ACUR is priced at $0.02, while SHEZF trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas SHEZF's P/E ratio is -23.48. In terms of profitability, ACUR's ROE is +0.00%, compared to SHEZF's ROE of +0.05%. Regarding short-term risk, ACUR is more volatile compared to SHEZF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs CHIZF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, CHIZF has a market cap of 1.7B. Regarding current trading prices, ACUR is priced at $0.02, while CHIZF trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas CHIZF's P/E ratio is 16.80. In terms of profitability, ACUR's ROE is +0.00%, compared to CHIZF's ROE of +0.04%. Regarding short-term risk, ACUR is more volatile compared to CHIZF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs YIHCF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, YIHCF has a market cap of 1.6B. Regarding current trading prices, ACUR is priced at $0.02, while YIHCF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas YIHCF's P/E ratio is -5.00. In terms of profitability, ACUR's ROE is +0.00%, compared to YIHCF's ROE of +0.19%. Regarding short-term risk, ACUR is more volatile compared to YIHCF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs SMDPY Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, SMDPY has a market cap of 1.6B. Regarding current trading prices, ACUR is priced at $0.02, while SMDPY trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas SMDPY's P/E ratio is 10.00. In terms of profitability, ACUR's ROE is +0.00%, compared to SMDPY's ROE of -1.44%. Regarding short-term risk, ACUR is more volatile compared to SMDPY. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs NPPNY Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, NPPNY has a market cap of 1.6B. Regarding current trading prices, ACUR is priced at $0.02, while NPPNY trades at $5.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas NPPNY's P/E ratio is 7.06. In terms of profitability, ACUR's ROE is +0.00%, compared to NPPNY's ROE of +0.09%. Regarding short-term risk, ACUR is more volatile compared to NPPNY. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs NPNKF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, NPNKF has a market cap of 1.6B. Regarding current trading prices, ACUR is priced at $0.02, while NPNKF trades at $23.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas NPNKF's P/E ratio is 7.02. In terms of profitability, ACUR's ROE is +0.00%, compared to NPNKF's ROE of +0.09%. Regarding short-term risk, ACUR is more volatile compared to NPNKF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs KARBF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, KARBF has a market cap of 1.5B. Regarding current trading prices, ACUR is priced at $0.02, while KARBF trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas KARBF's P/E ratio is 262.50. In terms of profitability, ACUR's ROE is +0.00%, compared to KARBF's ROE of N/A. Regarding short-term risk, ACUR is more volatile compared to KARBF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs EVOTF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, EVOTF has a market cap of 1.5B. Regarding current trading prices, ACUR is priced at $0.02, while EVOTF trades at $8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas EVOTF's P/E ratio is -7.52. In terms of profitability, ACUR's ROE is +0.00%, compared to EVOTF's ROE of -0.22%. Regarding short-term risk, ACUR is more volatile compared to EVOTF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs ARSUF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, ARSUF has a market cap of 1.5B. Regarding current trading prices, ACUR is priced at $0.02, while ARSUF trades at $20.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas ARSUF's P/E ratio is 18.05. In terms of profitability, ACUR's ROE is +0.00%, compared to ARSUF's ROE of +0.16%. Regarding short-term risk, ACUR is more volatile compared to ARSUF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs GTBIF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, GTBIF has a market cap of 1.2B. Regarding current trading prices, ACUR is priced at $0.02, while GTBIF trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas GTBIF's P/E ratio is 25.00. In terms of profitability, ACUR's ROE is +0.00%, compared to GTBIF's ROE of +0.03%. Regarding short-term risk, ACUR is more volatile compared to GTBIF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs SWGHF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, SWGHF has a market cap of 1.1B. Regarding current trading prices, ACUR is priced at $0.02, while SWGHF trades at $11.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas SWGHF's P/E ratio is 15.78. In terms of profitability, ACUR's ROE is +0.00%, compared to SWGHF's ROE of +0.10%. Regarding short-term risk, ACUR is more volatile compared to SWGHF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs GNMLF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, GNMLF has a market cap of 1.1B. Regarding current trading prices, ACUR is priced at $0.02, while GNMLF trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas GNMLF's P/E ratio is 10.36. In terms of profitability, ACUR's ROE is +0.00%, compared to GNMLF's ROE of +0.12%. Regarding short-term risk, ACUR is more volatile compared to GNMLF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs KKPCF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, KKPCF has a market cap of 1B. Regarding current trading prices, ACUR is priced at $0.02, while KKPCF trades at $26.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas KKPCF's P/E ratio is 10.76. In terms of profitability, ACUR's ROE is +0.00%, compared to KKPCF's ROE of +0.04%. Regarding short-term risk, ACUR is more volatile compared to KKPCF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs KSPHF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, KSPHF has a market cap of 994.3M. Regarding current trading prices, ACUR is priced at $0.02, while KSPHF trades at $23.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas KSPHF's P/E ratio is 12.16. In terms of profitability, ACUR's ROE is +0.00%, compared to KSPHF's ROE of +0.05%. Regarding short-term risk, ACUR is more volatile compared to KSPHF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs CASBF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, CASBF has a market cap of 984.2M. Regarding current trading prices, ACUR is priced at $0.02, while CASBF trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas CASBF's P/E ratio is -15.24. In terms of profitability, ACUR's ROE is +0.00%, compared to CASBF's ROE of -0.14%. Regarding short-term risk, ACUR is more volatile compared to CASBF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs SHPHF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, SHPHF has a market cap of 924.4M. Regarding current trading prices, ACUR is priced at $0.02, while SHPHF trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas SHPHF's P/E ratio is -3.33. In terms of profitability, ACUR's ROE is +0.00%, compared to SHPHF's ROE of -0.01%. Regarding short-term risk, ACUR is more volatile compared to SHPHF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs BIOGY Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, BIOGY has a market cap of 914.8M. Regarding current trading prices, ACUR is priced at $0.02, while BIOGY trades at $9.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas BIOGY's P/E ratio is 29.03. In terms of profitability, ACUR's ROE is +0.00%, compared to BIOGY's ROE of +0.18%. Regarding short-term risk, ACUR is more volatile compared to BIOGY. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs LVTTF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, LVTTF has a market cap of 893M. Regarding current trading prices, ACUR is priced at $0.02, while LVTTF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas LVTTF's P/E ratio is -0.02. In terms of profitability, ACUR's ROE is +0.00%, compared to LVTTF's ROE of +0.00%. Regarding short-term risk, ACUR is less volatile compared to LVTTF. This indicates potentially lower risk in terms of short-term price fluctuations for ACUR.
ACUR vs EVRRF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, EVRRF has a market cap of 889.2M. Regarding current trading prices, ACUR is priced at $0.02, while EVRRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas EVRRF's P/E ratio is -0.08. In terms of profitability, ACUR's ROE is +0.00%, compared to EVRRF's ROE of +2.97%. Regarding short-term risk, ACUR is more volatile compared to EVRRF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs NRXCF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, NRXCF has a market cap of 839.4M. Regarding current trading prices, ACUR is priced at $0.02, while NRXCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas NRXCF's P/E ratio is -0.22. In terms of profitability, ACUR's ROE is +0.00%, compared to NRXCF's ROE of +2.32%. Regarding short-term risk, ACUR is more volatile compared to NRXCF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs TWAPF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, TWAPF has a market cap of 828.5M. Regarding current trading prices, ACUR is priced at $0.02, while TWAPF trades at $16.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas TWAPF's P/E ratio is 6.28. In terms of profitability, ACUR's ROE is +0.00%, compared to TWAPF's ROE of +0.09%. Regarding short-term risk, ACUR is more volatile compared to TWAPF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs CSWYF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, CSWYF has a market cap of 815.8M. Regarding current trading prices, ACUR is priced at $0.02, while CSWYF trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas CSWYF's P/E ratio is 5.14. In terms of profitability, ACUR's ROE is +0.00%, compared to CSWYF's ROE of +0.07%. Regarding short-term risk, ACUR is more volatile compared to CSWYF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs TCNNF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, TCNNF has a market cap of 775.6M. Regarding current trading prices, ACUR is priced at $0.02, while TCNNF trades at $4.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas TCNNF's P/E ratio is -5.14. In terms of profitability, ACUR's ROE is +0.00%, compared to TCNNF's ROE of -0.13%. Regarding short-term risk, ACUR is more volatile compared to TCNNF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs TRXPF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, TRXPF has a market cap of 690.7M. Regarding current trading prices, ACUR is priced at $0.02, while TRXPF trades at $24.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas TRXPF's P/E ratio is 25.86. In terms of profitability, ACUR's ROE is +0.00%, compared to TRXPF's ROE of +0.04%. Regarding short-term risk, ACUR is more volatile compared to TRXPF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs SWDCF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, SWDCF has a market cap of 679.3M. Regarding current trading prices, ACUR is priced at $0.02, while SWDCF trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas SWDCF's P/E ratio is 70.83. In terms of profitability, ACUR's ROE is +0.00%, compared to SWDCF's ROE of +0.01%. Regarding short-term risk, ACUR is more volatile compared to SWDCF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs NIKA Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, NIKA has a market cap of 667.1M. Regarding current trading prices, ACUR is priced at $0.02, while NIKA trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas NIKA's P/E ratio is N/A. In terms of profitability, ACUR's ROE is +0.00%, compared to NIKA's ROE of +0.39%. Regarding short-term risk, ACUR is more volatile compared to NIKA. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs CURLF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, CURLF has a market cap of 666.4M. Regarding current trading prices, ACUR is priced at $0.02, while CURLF trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas CURLF's P/E ratio is -2.67. In terms of profitability, ACUR's ROE is +0.00%, compared to CURLF's ROE of -0.25%. Regarding short-term risk, ACUR is more volatile compared to CURLF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs TRSSF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, TRSSF has a market cap of 601.9M. Regarding current trading prices, ACUR is priced at $0.02, while TRSSF trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas TRSSF's P/E ratio is -1.32. In terms of profitability, ACUR's ROE is +0.00%, compared to TRSSF's ROE of -0.32%. Regarding short-term risk, ACUR is more volatile compared to TRSSF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs ELTP Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, ELTP has a market cap of 569.3M. Regarding current trading prices, ACUR is priced at $0.02, while ELTP trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas ELTP's P/E ratio is -26.65. In terms of profitability, ACUR's ROE is +0.00%, compared to ELTP's ROE of -0.36%. Regarding short-term risk, ACUR is more volatile compared to ELTP. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs SGFEF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, SGFEF has a market cap of 532.5M. Regarding current trading prices, ACUR is priced at $0.02, while SGFEF trades at $102.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas SGFEF's P/E ratio is 22.93. In terms of profitability, ACUR's ROE is +0.00%, compared to SGFEF's ROE of +0.11%. Regarding short-term risk, ACUR is more volatile compared to SGFEF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs CCHWF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, CCHWF has a market cap of 521.3M. Regarding current trading prices, ACUR is priced at $0.02, while CCHWF trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas CCHWF's P/E ratio is -1.12. In terms of profitability, ACUR's ROE is +0.00%, compared to CCHWF's ROE of -7.05%. Regarding short-term risk, ACUR is more volatile compared to CCHWF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs AIHLF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, AIHLF has a market cap of 507.8M. Regarding current trading prices, ACUR is priced at $0.02, while AIHLF trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas AIHLF's P/E ratio is 10.83. In terms of profitability, ACUR's ROE is +0.00%, compared to AIHLF's ROE of +0.15%. Regarding short-term risk, ACUR is more volatile compared to AIHLF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs BOIRF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, BOIRF has a market cap of 494.8M. Regarding current trading prices, ACUR is priced at $0.02, while BOIRF trades at $28.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas BOIRF's P/E ratio is 20.07. In terms of profitability, ACUR's ROE is +0.00%, compared to BOIRF's ROE of +0.06%. Regarding short-term risk, ACUR is more volatile compared to BOIRF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs PEXXF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, PEXXF has a market cap of 463.1M. Regarding current trading prices, ACUR is priced at $0.02, while PEXXF trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas PEXXF's P/E ratio is 9.00. In terms of profitability, ACUR's ROE is +0.00%, compared to PEXXF's ROE of N/A. Regarding short-term risk, ACUR is more volatile compared to PEXXF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs MITPF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, MITPF has a market cap of 451.6M. Regarding current trading prices, ACUR is priced at $0.02, while MITPF trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas MITPF's P/E ratio is -3.05. In terms of profitability, ACUR's ROE is +0.00%, compared to MITPF's ROE of +4.92%. Regarding short-term risk, ACUR is more volatile compared to MITPF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs CNGGF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, CNGGF has a market cap of 423.8M. Regarding current trading prices, ACUR is priced at $0.02, while CNGGF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas CNGGF's P/E ratio is -0.10. In terms of profitability, ACUR's ROE is +0.00%, compared to CNGGF's ROE of -1.60%. Regarding short-term risk, ACUR is more volatile compared to CNGGF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs KHTRF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, KHTRF has a market cap of 415.5M. Regarding current trading prices, ACUR is priced at $0.02, while KHTRF trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas KHTRF's P/E ratio is 59.59. In terms of profitability, ACUR's ROE is +0.00%, compared to KHTRF's ROE of +0.01%. Regarding short-term risk, ACUR is more volatile compared to KHTRF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs AGYTF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, AGYTF has a market cap of 405.1M. Regarding current trading prices, ACUR is priced at $0.02, while AGYTF trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas AGYTF's P/E ratio is -8.50. In terms of profitability, ACUR's ROE is +0.00%, compared to AGYTF's ROE of -2.67%. Regarding short-term risk, ACUR is more volatile compared to AGYTF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs GLASF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, GLASF has a market cap of 304.1M. Regarding current trading prices, ACUR is priced at $0.02, while GLASF trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas GLASF's P/E ratio is -66.02. In terms of profitability, ACUR's ROE is +0.00%, compared to GLASF's ROE of +0.00%. Regarding short-term risk, ACUR is more volatile compared to GLASF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs PKBFF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, PKBFF has a market cap of 288.4M. Regarding current trading prices, ACUR is priced at $0.02, while PKBFF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas PKBFF's P/E ratio is -0.00. In terms of profitability, ACUR's ROE is +0.00%, compared to PKBFF's ROE of +7.96%. Regarding short-term risk, ACUR is more volatile compared to PKBFF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs BHCCF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, BHCCF has a market cap of 271.2M. Regarding current trading prices, ACUR is priced at $0.02, while BHCCF trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas BHCCF's P/E ratio is -4.57. In terms of profitability, ACUR's ROE is +0.00%, compared to BHCCF's ROE of -0.18%. Regarding short-term risk, ACUR is more volatile compared to BHCCF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs VRNOF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, VRNOF has a market cap of 240.1M. Regarding current trading prices, ACUR is priced at $0.02, while VRNOF trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas VRNOF's P/E ratio is -0.67. In terms of profitability, ACUR's ROE is +0.00%, compared to VRNOF's ROE of -0.22%. Regarding short-term risk, ACUR is more volatile compared to VRNOF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs CPHRF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, CPHRF has a market cap of 232.1M. Regarding current trading prices, ACUR is priced at $0.02, while CPHRF trades at $9.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas CPHRF's P/E ratio is 25.17. In terms of profitability, ACUR's ROE is +0.00%, compared to CPHRF's ROE of +0.09%. Regarding short-term risk, ACUR is more volatile compared to CPHRF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs CRLBF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, CRLBF has a market cap of 221.7M. Regarding current trading prices, ACUR is priced at $0.02, while CRLBF trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas CRLBF's P/E ratio is -2.99. In terms of profitability, ACUR's ROE is +0.00%, compared to CRLBF's ROE of -0.16%. Regarding short-term risk, ACUR is more volatile compared to CRLBF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs PLNHF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, PLNHF has a market cap of 202M. Regarding current trading prices, ACUR is priced at $0.02, while PLNHF trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas PLNHF's P/E ratio is -3.50. In terms of profitability, ACUR's ROE is +0.00%, compared to PLNHF's ROE of -0.34%. Regarding short-term risk, ACUR is more volatile compared to PLNHF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs HUMDF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, HUMDF has a market cap of 147.5M. Regarding current trading prices, ACUR is priced at $0.02, while HUMDF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas HUMDF's P/E ratio is -3.75. In terms of profitability, ACUR's ROE is +0.00%, compared to HUMDF's ROE of +8.06%. Regarding short-term risk, ACUR is more volatile compared to HUMDF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs COPHF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, COPHF has a market cap of 131.7M. Regarding current trading prices, ACUR is priced at $0.02, while COPHF trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas COPHF's P/E ratio is -0.02. In terms of profitability, ACUR's ROE is +0.00%, compared to COPHF's ROE of -5.75%. Regarding short-term risk, ACUR is less volatile compared to COPHF. This indicates potentially lower risk in terms of short-term price fluctuations for ACUR.
ACUR vs STMH Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, STMH has a market cap of 125.8M. Regarding current trading prices, ACUR is priced at $0.02, while STMH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas STMH's P/E ratio is N/A. In terms of profitability, ACUR's ROE is +0.00%, compared to STMH's ROE of -2.75%. Regarding short-term risk, ACUR is less volatile compared to STMH. This indicates potentially lower risk in terms of short-term price fluctuations for ACUR.
ACUR vs PHCUF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, PHCUF has a market cap of 115.1M. Regarding current trading prices, ACUR is priced at $0.02, while PHCUF trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas PHCUF's P/E ratio is 432.00. In terms of profitability, ACUR's ROE is +0.00%, compared to PHCUF's ROE of +0.00%. Regarding short-term risk, ACUR is more volatile compared to PHCUF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs LPCUF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, LPCUF has a market cap of 110.8M. Regarding current trading prices, ACUR is priced at $0.02, while LPCUF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas LPCUF's P/E ratio is 18.82. In terms of profitability, ACUR's ROE is +0.00%, compared to LPCUF's ROE of +0.05%. Regarding short-term risk, ACUR is more volatile compared to LPCUF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs CNVCF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, CNVCF has a market cap of 109.2M. Regarding current trading prices, ACUR is priced at $0.02, while CNVCF trades at $6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas CNVCF's P/E ratio is -5.00. In terms of profitability, ACUR's ROE is +0.00%, compared to CNVCF's ROE of +9.56%. Regarding short-term risk, ACUR is more volatile compared to CNVCF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs HLTRF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, HLTRF has a market cap of 102.4M. Regarding current trading prices, ACUR is priced at $0.02, while HLTRF trades at $3.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas HLTRF's P/E ratio is -5.65. In terms of profitability, ACUR's ROE is +0.00%, compared to HLTRF's ROE of -0.24%. Regarding short-term risk, ACUR is more volatile compared to HLTRF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs BIOYF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, BIOYF has a market cap of 98.7M. Regarding current trading prices, ACUR is priced at $0.02, while BIOYF trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas BIOYF's P/E ratio is 17.92. In terms of profitability, ACUR's ROE is +0.00%, compared to BIOYF's ROE of +0.20%. Regarding short-term risk, ACUR is more volatile compared to BIOYF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs ABSCF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, ABSCF has a market cap of 95M. Regarding current trading prices, ACUR is priced at $0.02, while ABSCF trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas ABSCF's P/E ratio is -9.41. In terms of profitability, ACUR's ROE is +0.00%, compared to ABSCF's ROE of +0.26%. Regarding short-term risk, ACUR is more volatile compared to ABSCF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs GRUSF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, GRUSF has a market cap of 88.6M. Regarding current trading prices, ACUR is priced at $0.02, while GRUSF trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas GRUSF's P/E ratio is -7.15. In terms of profitability, ACUR's ROE is +0.00%, compared to GRUSF's ROE of -0.89%. Regarding short-term risk, ACUR is more volatile compared to GRUSF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs LRDSF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, LRDSF has a market cap of 83.6M. Regarding current trading prices, ACUR is priced at $0.02, while LRDSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas LRDSF's P/E ratio is -0.01. In terms of profitability, ACUR's ROE is +0.00%, compared to LRDSF's ROE of +1.61%. Regarding short-term risk, ACUR is more volatile compared to LRDSF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs GBLP Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, GBLP has a market cap of 83M. Regarding current trading prices, ACUR is priced at $0.02, while GBLP trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas GBLP's P/E ratio is -0.67. In terms of profitability, ACUR's ROE is +0.00%, compared to GBLP's ROE of +0.31%. Regarding short-term risk, ACUR is more volatile compared to GBLP. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs LOVFF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, LOVFF has a market cap of 83M. Regarding current trading prices, ACUR is priced at $0.02, while LOVFF trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas LOVFF's P/E ratio is 9.07. In terms of profitability, ACUR's ROE is +0.00%, compared to LOVFF's ROE of +0.15%. Regarding short-term risk, ACUR is more volatile compared to LOVFF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs CBWTF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, CBWTF has a market cap of 78.8M. Regarding current trading prices, ACUR is priced at $0.02, while CBWTF trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas CBWTF's P/E ratio is 3.00. In terms of profitability, ACUR's ROE is +0.00%, compared to CBWTF's ROE of -0.15%. Regarding short-term risk, ACUR is more volatile compared to CBWTF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs PLNH Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, PLNH has a market cap of 74.2M. Regarding current trading prices, ACUR is priced at $0.02, while PLNH trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas PLNH's P/E ratio is -1.63. In terms of profitability, ACUR's ROE is +0.00%, compared to PLNH's ROE of -0.32%. Regarding short-term risk, ACUR is more volatile compared to PLNH. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs EOFBY Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, EOFBY has a market cap of 73.7M. Regarding current trading prices, ACUR is priced at $0.02, while EOFBY trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas EOFBY's P/E ratio is -7.67. In terms of profitability, ACUR's ROE is +0.00%, compared to EOFBY's ROE of N/A. Regarding short-term risk, ACUR is more volatile compared to EOFBY. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.
ACUR vs MEDXF Comparison
ACUR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACUR stands at 1.3M. In comparison, MEDXF has a market cap of 67.4M. Regarding current trading prices, ACUR is priced at $0.02, while MEDXF trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACUR currently has a P/E ratio of -1.00, whereas MEDXF's P/E ratio is 13.93. In terms of profitability, ACUR's ROE is +0.00%, compared to MEDXF's ROE of +0.11%. Regarding short-term risk, ACUR is more volatile compared to MEDXF. This indicates potentially higher risk in terms of short-term price fluctuations for ACUR.